Among the growing companies to invest in, these Blue chip stocks jumped after recent quarter updates
RESMED Inc (ASX: RMD)
ResMed Inc. in the third quarter of fiscal year 2025 demonstrated strong financial and operational performance marked by consistent growth and innovation in sleep and respiratory care. Revenue for the quarter ending March 31, 2025 reached $1.29 billion representing an 8% Y-o-Y increase and 9% rise on a constant currency basis. This growth was driven primarily by heightened demand for sleep devices, masks and the Residential Care Software portfolio which alone experienced a 10% uptick. The U.S., Canada and Latin America markets saw a 9% revenue increase while Europe, Asia and other regions achieved 8% growth on a constant currency basis.
ResMed, one of the best growth stocks, also saw a notable improvement in its financial metrics with gross margin increasing by 140 basis points to 59.3% and non-GAAP gross margin reaching 59.9%. Operating income increased by 14% to reach $426.3 million, while net income experienced a notable 21% jump amounting to $365 million. Diluted earnings per share were $2.48 with non-GAAP EPS at $2.37. The quarter generated a strong operating cash flow of $579 million, which included $107 million received in tax refunds from the IRS. Also, the operating cash flow stood at $471 million indicating strong underlying financial health.
Key operational developments featured the nationwide launch of NightOwl an FDA-approved home sleep apnea diagnostic tool, along with a strategic brand refresh aimed at strengthening global brand presence. The company published a meta analysis in The Lancet Respiratory Medicine affirming the life-saving efficacy of CPAP therapy for obstructive sleep apnea. ResMed was also recognized as one of LexisNexis “Top 100 Global Innovators.” Looking ahead, the firm remains focused on addressing the global sleep and breathing health crisis affecting over 2.3 billion people with ongoing investments in innovation and patient-centric digital health solutions.
NEWMONT CORPORATION (ASX: NEM)
Newmont Corporation started off 2025 with a powerful performance reflecting both strategic excellence and robust financial health. The company reported a net income of $1.9 billion and an adjusted net income of $1.25 per diluted share in Q1 along with a record free cash flow of $1.2 billion. This performance was supported by the production of 1.5 million attributable gold ounces primarily from its Tier 1 Portfolio and 35 thousand tonnes of copper. The average realized price for gold climbed to $2,944 per ounce representing a marked improvement over the previous quarter.
The successful completion of Newmont’s non-core asset divestiture program raising up to $4.3 billion in gross proceeds is one of the key highlights of the quarter. Key transactions included the sales of Musselwhite, Eleonore, Cripple Creek and Victor, Akyem and Porcupine which collectively generated over $2.5 billion in after-tax cash proceeds. These strategic moves not only streamlined the company's portfolio but also strengthened its liquidity ending the quarter with $4.7 billion in cash and $8.8 billion in total liquidity.
The company showcased its operational efficiency through consistent capital discipline and a strong focus on sustainability. NEM dedicated $95 million to reclamation efforts with $50 million specifically allocated to building water treatment plants at Yanacocha highlighting its ongoing dedication to responsible mining practices. It also reduced debt by $1.0 billion improving its net debt to adjusted EBITDA ratio to 0.3x. They also delivered $1.0 billion in shareholder returns through dividends and share repurchases. Building on a strong start to the year and staying closely aligned with its 2025 objectives, Newmont is well-positioned to strengthen its role as a global leader in gold and copper production guided by its commitment to sustainability and long-term value for shareholders.
(Source: Company Announcements)
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
